| Literature DB >> 32493476 |
Casper T Briels1,2, Deborah N Schoonhoven3,4, Cornelis J Stam4, Hanneke de Waal3, Philip Scheltens3, Alida A Gouw4.
Abstract
BACKGROUND: Although numerous electroencephalogram (EEG) studies have described differences in functional connectivity in Alzheimer's disease (AD) compared to healthy subjects, there is no general consensus on the methodology of estimating functional connectivity in AD. Inconsistent results are reported due to multiple methodological factors such as diagnostic criteria, small sample sizes and the use of functional connectivity measures sensitive to volume conduction. We aimed to investigate the reproducibility of the disease-associated effects described by commonly used functional connectivity measures with respect to the amyloid, tau and neurodegeneration (A/T/N) criteria.Entities:
Keywords: Alzheimer’s disease; EEG; Functional connectivity; Reproducibility
Mesh:
Year: 2020 PMID: 32493476 PMCID: PMC7271479 DOI: 10.1186/s13195-020-00632-3
Source DB: PubMed Journal: Alzheimers Res Ther Impact factor: 6.982
The equations of the used functional connectivity measures. For each functional connectivity measure, it is indicated whether they observe associations between signals based on amplitude (A), phase (P) or both (A/P)
| Measure | Equation | |
|---|---|---|
| 1. Coherency | A/P | |
| 2. Phase locking value/phase coherence | P | |
| 3. Amplitude envelope | A | |
| 4. Imaginary coherence | A/P | |
| 5. Phase lag index | P | PLI = |〈 |
| 6. Weighted phase lag index | P |
Characteristics of subjective cognitive decline (SCD) and dementia due to Alzheimer’s disease (AD) subjects in both cohorts. The count (n), mean or median with percentage (%), standard deviation (SD) or interquartile range (IQR) are shown for each variable. MMSE Mini-Mental State Exam, CNS central nervous system, MTA Medial Temporal Atrophy score, Aβ 1–42 amyloid beta 1–42, t-tau total tau, p-tau phosphorylated tau
| Cohort 1 | Cohort 2 | |||
|---|---|---|---|---|
| Characteristic | SCD | AD | SCD | AD |
| Female ( | 76 (39%) | 104 (49%) | 89 (44%) | 94 (48%) |
| Age (mean, SD) | 62 ± 8 | 67 ± 8a | 60 ± 10 | 69 ± 10a |
| MMSE (median, IQR) | 28 (27–29) | 21 (17–24)a | 29 (28–30)b | 22 (18–25)a,b |
| Vascular disease ( | 34 (17%) | 40 (19%) | 35 (17%) | 32 (16%) |
| CNS disease ( | 20 (10%) | 14 (7%) | 22 (11%) | 19 (10%) |
| Psychiatric disease ( | 6 (3%) | 8 (4%) | 5 (2%) | 1 (1%) |
| Antidepressants ( | 20 (10%) | 26 (12%) | 16 (8%) | 19 (10%) |
| Benzodiazepines ( | 11 (6%) | 12 (6%) | 18 (9%) | 15 (8%) |
| Anti-epileptic drugs ( | 4 (2%) | 3 (1%) | 4 (2%) | 3 (2%) |
| Acetylcholinesterase inhibitors ( | 0 (0%) | 16 (7%)a | 1 (0%) | 18 (9%)a |
| MTA (median, IQR) | 0 (0–0.5) | 1 (0.5–2)a | 0 (0–0.5) | 1.5 (1–2.5)a,b |
| Fazekas (median, IQR) | 1 (0–1) | 1 (0–1) | 0 (0–1) | 1 (0.5–1)a |
| Aβ 1–42 (mean, SD) | 1031 ± 268 | 663 ± 136a | 1090 ± 197 | 694 ± 162a |
| t-tau (mean, SD) | 302 ± 214 | 731 ± 413a | 267 ± 119 | 610 ± 321a,b |
| p-tau (mean, SD) | 50 ± 23 | 89 ± 35a | 47 ± 16 | 85 ± 38a |
| Positive PET ( | 12 (38%) | 34 (100%)a | 3 (27%) | 14 (82%)a |
aSignificant differences between SCD and AD subjects within cohorts (p < 0.05)
bSignificant differences in the same diagnostic group across cohorts (e.g. SCD versus SCD and AD versus AD) (p < 0.05)
Fig. 1Summary of observed differences in ANOVA model 1, shown as effect size (Cohen’s d), between AD and SCD subjects for each of the functional connectivity measures and bandwidths. The significant effect sizes of the comparisons made in the entire cohort 1 (n = 411) are shown. Effects that could not be reproduced in the subset populations or cohort 2 were left out. Red blocks represent a higher and blue blocks a lower level of functional connectivity in AD subjects compared to SCD subjects. The size of the blocks and the number shown in the blocks represent the size of the effect. Results of functional measures susceptible to signal leakage are shaded in grey
Fig. 2The difference in functional connectivity between SCD and AD subjects per bandwidth is shown for each cohort and subpopulation. Significant effect sizes are shown in Cohen’s d estimated by GLM model 1. Cohort 1: all SCD and AD subjects in cohort 1. Cohort 2: all SCD and AD subjects in cohort 2. Cohort 1 A/T: amyloid-negative/tau-negative SCD versus amyloid-positive/tau-positive AD subjects from cohort 1 (subpopulation 1). Cohort 1 A/T/N: amyloid-negative/tau-negative/MTA < 1 SCD versus amyloid-positive/tau-positive/MTA ≥ 1 AD subjects from cohort 1, excluding any patients with Fazekas > 1 and any potential interfering medication (subpopulation 2)
Fig. 3Correlation of different functional connectivity measures with the relative power in the corresponding frequency band. The functional connectivity measures are shown on the x-axis and the band power on the y-axis. Only significant correlations are shown, indicated by the correlation coefficient (r) which is also indicated by the colour gradient from r = − 1 (dark red) to r = + 1 (dark blue)
Fig. 4Summary of observed differences in ANOVA model 2, shown as effect size (Cohen’s d), between AD and SCD subjects for each of the functional connectivity measures and bandwidth. The significant effect sizes of the comparisons made in the entire cohort 1 (n = 411) are shown. Effects that could not be reproduced in the subset populations or cohort 2 were left out. Red blocks represent a higher and blue blocks a lower level of functional connectivity in AD subjects compared to SCD subjects. The size of the blocks and the number shown in the blocks represent the size of the effect. Results of functional measures susceptible to signal leakage are shaded in grey
Pearson correlation coefficients (r) between functional connectivity (FC) and disease severity represented by MMSE. Correlations were estimated for the entire population (cohorts 1 and 2) and the AD subjects only. Bold r values indicate a significant (p < 0.05) correlation
| FC measure versus MMSE | All subjects ( | AD only ( | ||
|---|---|---|---|---|
| iCoh | 1.41 × 10−4 | − 0.06 | 0.23 | |
| PLI | 2.79 × 10−4 | − 0.06 | 0.23 | |
| wPLI | 1.71 × 10−4 | − 0.06 | 0.21 | |
| AEC-c | 3.2 × 10−9 | 0.0054 | ||
| AEC | 6.1 × 10−25 | 0.0065 | ||
| Coh | 6.4 × 10−15 | 0.04 | 0.40 | |
| PLV | 7.3 × 10−11 | 0.08 | 0.13 | |
| AEC-c | 1.8 × 10−9 | 0.08 | 0.12 | |
| AEC | 1.0 × 10−13 | 0.0073 | ||
| Coh | 3.1 × 10−10 | 0.015 | ||